drugset / Trial / NCT01626339

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

NCT01626339

Unknown 30 enrolled University of Malaya

Summary

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Timeline

Start
2012-04
Primary completion
2012-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody Intravitreal
Subject Ranibizumab Monoclonal antibody Intravitreal